Podcasts about Batra

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

From April 5, 2007: Oprah talks to parents and siblings of children on the autism spectrum about how this condition affects their lives. Dr. Anshu Batra, a developmental-behavioral pediatric specialist, discusses the three behavioral deficits that define autism, possible causes and early warning signs. Dr. Batra also opens up about the symptoms of her own autistic children and shares coping strategies parents can put in place. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Siddharth Bajaj is a seasoned marketing executive and Chief Marketing Officer at Dr Batra's Positive Clinics, where he leads brand communications and growth strategies. With around 20 years of experience across B2C and B2B sectors—including BFSI, supply chain, AgriTech, FMCG, and healthcare—he's known for driving impactful campaigns, strategic planning, and customer engagement initiatives globally. His work blends strategic vision with MarTech to optimize omnichannel outreach, and he's led brand launches and high-visibility marketing efforts across international markets. Siddharth holds a master's in advertising and public relations and a bachelor's in computer science.

In this episode of Beauty Bytes, I am exploring the frontier of needle-free regenerative medicine with Dr. Sanjay Batra, a globally recognized scientist and the creator of Juvasonic. We discuss how his device uses a unique combination of sonic vibration and dermabrasion to open the stratum corneum for 10-15 minutes, allowing large molecules like exosomes, polynucleotides, and PRP to penetrate deep into the dermis without a single needle prick.Dr. Batra shares why microneedling might not be the best delivery method for serums (hint: the bleeding actually pushes products out!) and reveals incredible data on using this technology for hair density and restoration . We also cover a fascinating off-label use: how Juvasonic can potentially break down filler nodules (like Radiesse lumps) in just seconds without invasive measures . This is the future of pain-free, high-compliance aesthetic care.

Legendary director Mira Nair and Cannes-winner Ritesh Batra made two very different hit films about very different sides of India's fabled food delivery system. Batra tells Rico about the romance of dabbawallas, while Nair remembers the mean streets of Mumbai's chaiwallas (and what she serves her son Zohran Mamdani at home).Just in time for holiday eat-a-thons, the award-winning MUBI Podcast is back and celebrating its tenth season with a four-course serving of stories about food on film. Titled "A Feast For The Eyes," the season digs into the ways filmmakers use food to provoke hunger, thought, nausea, political action...and sometimes all the above.Joining host Rico Gagliano is a sampler platter of luminaries from the film and culinary world, including directors Brad Bird (RATATOUILLE), Mira Nair (MONSOON WEDDING), and David Gelb (JIRO DREAMS OF SUSHI), former New York Times food writer Alison Roman, and more. Gluttons for great cinema stories can start chowing down on episodes weekly, starting Thanksgiving Day.Let's Eat! Food and Film collection is now streaming on MUBI globally.THE LUNCHBOX is now streaming on MUBI in the UK, Ireland, Australia, Latin America and Netherlands. To stream some of the films we've covered on the podcast, check out the collection Featured on the MUBI Podcast. Availability of films varies depending on your country.MUBI is a global streaming service, production company and film distributor dedicated to elevating great cinema. MUBI makes, acquires, curates, and champions extraordinary films, connecting them to audiences all over the world. A place to discover ambitious new films and singular voices, from iconic directors to emerging auteurs. Each carefully chosen by MUBI's curators.

In this episode of The Sound of Economics, host Rebecca Christie is joined by Professor Amita Batra, of Jawaharlal Nehru University's Centre for South Asian Studies, and Bruegel Senior Fellow Ignacio Garcia Bercero to discuss the European Union-India trade relationship and its potential. What scope is there for a free trade agreement, particularly regarding tricky sectors like steel and automotive manufacturing? How will Europe's new Carbon Border Adjustment Mechanism affect the dynamic? Is there room for closer cooperation given the geopolitical pressures posed by the United States and China? Working together, India's growth and the EU's trade experience have the potential to find more common ground, if political obstacles can be overcome. Related research:  Batra, A. (2022) India's Trade Policy in the 21st Century, Routledge García-Bercero, I. and A. Sapir (2025) ‘The time is right to make a European Union-India trade deal happen', Policy Brief 19/2025, Bruegel

Value: After Hours is a podcast about value investing, Fintwit, and all things finance and investment by investors Tobias Carlisle, and Jake Taylor. ⁠⁠⁠⁠⁠⁠⁠Soldier of Fortune: Warren Buffett, Sun Tzu and the Ancient Art of Risk-Taking⁠⁠⁠⁠⁠⁠⁠ (⁠⁠⁠⁠⁠⁠⁠Kindle⁠⁠⁠⁠⁠⁠⁠)We are live every Tuesday at 1.30pm E / 10.30am P.See our latest episodes at https://acquirersmultiple.com/podcastAbout Jake Jake's Twitter: https://twitter.com/farnamjake1Jake's book: The Rebel Allocator https://amzn.to/2sgip3lABOUT THE PODCASTHi, I'm Tobias Carlisle. I launched The Acquirers Podcast to discuss the process of finding undervalued stocks, deep value investing, hedge funds, activism, buyouts, and special situations.We uncover the tactics and strategies for finding good investments, managing risk, dealing with bad luck, and maximizing success.SEE LATEST EPISODEShttps://acquirersmultiple.com/podcast/SEE OUR FREE DEEP VALUE STOCK SCREENER https://acquirersmultiple.com/screener/FOLLOW TOBIASWebsite: https://acquirersmultiple.com/Firm: https://acquirersfunds.com/ Twitter: ttps://twitter.com/GreenbackdLinkedIn: https://www.linkedin.com/in/tobycarlisleFacebook: https://www.facebook.com/tobiascarlisleInstagram: https://www.instagram.com/tobias_carlisleABOUT TOBIAS CARLISLETobias Carlisle is the founder of The Acquirer's Multiple®, and Acquirers Funds®. He is best known as the author of the #1 new release in Amazon's Business and Finance The Acquirer's Multiple: How the Billionaire Contrarians of Deep Value Beat the Market, the Amazon best-sellers Deep Value: Why Activists Investors and Other Contrarians Battle for Control of Losing Corporations (2014) (https://amzn.to/2VwvAGF), Quantitative Value: A Practitioner's Guide to Automating Intelligent Investment and Eliminating Behavioral Errors (2012) (https://amzn.to/2SDDxrN), and Concentrated Investing: Strategies of the World's Greatest Concentrated Value Investors (2016) (https://amzn.to/2SEEjVn). He has extensive experience in investment management, business valuation, public company corporate governance, and corporate law.Prior to founding the forerunner to Acquirers Funds in 2010, Tobias was an analyst at an activist hedge fund, general counsel of a company listed on the Australian Stock Exchange, and a corporate advisory lawyer. As a lawyer specializing in mergers and acquisitions he has advised on transactions across a variety of industries in the United States, the United Kingdom, China, Australia, Singapore, Bermuda, Papua New Guinea, New Zealand, and Guam. He is a graduate of the University of Queensland in Australia with degrees in Law (2001) and Business (Management) (1999).

Pyritz, Lennart; Batra, Anil www.deutschlandfunk.de, Sprechstunde

Send us a textJoe Watt co-founded ECMC Group's Education Impact Fund to back bold ideas expanding equity and opportunity in education. Today, he leads the Fund as Managing Director, shaping how patient, mission-driven capital creates lasting change. He's joined by Atin Batra, a Director at the Fund, who leads investments across the learner journey, bringing a global venture lens and a deep focus on measurable outcomes that improve learner success.

Reena Batra, vice president, data science, LexisNexis Risk Solutions, explains how falling rates, regional dynamics and direct digital channels are fueling a sharp rise in U.S. auto insurance shopping, with retention challenges pushing insurers to adopt more data-driven, customer-focused strategies.

On this episode of Daily Influence, host Gregg-Brooke Koleno sits down with Parminder Batra, co-founder and CEO of Track and Protect, a company transforming safety in the hospitality industry. With a background in law and risk mitigation, Parminder shares how her journey from attorney to tech founder was driven by a deeper calling: empowering women and creating safer work environments for hotel housekeepers. In this powerful conversation, Parminder opens up about: • The moment she realized her work could save lives, not just track inventory • How vulnerability and mutual accountability shape her company's leadership culture • The mindset shift that helped her overcome imposter syndrome • Why her annual birthday ritual of solo travel and self-reflection fuels her growth • What it really means to be a responsible, empowering leader This episode is a reminder that influence isn't about perfection—it's about showing up, lifting others, and believing you can figure things out. Tune in and get inspired by Parminder's wisdom, humor, and unwavering dedication to making the world safer—one button, one conversation, one empowered person at a time. Contact Parminder at parminder.batra@traknprotect.com

In this very special live recording of That's Total Mom Sense, host Kanika Chadda Gupta brings together community, culture, and conversation at OASES House in NYC. Joined by Sonam Sangmo (Partner and Creative Director of OASES) and Radhika Batra Shah (Founder of Radhika's Fine Teas & Whatnots), the panel explores what it means to be authentically South Asian living abroad, while honoring the origins of ancient traditions like yoga, ayurveda, and tea. From creating mindful spaces in a bustling city to preserving the heritage of tea as a ritual for wellness and connection, Sonam and Radhika share their journeys as entrepreneurs, women, and leaders rooted in purpose. Together, they discuss: The inspiration behind OASES and its role as a sanctuary for body, mind, and soul How tea can be more than a beverage — a daily practice of pause and presence Balancing entrepreneurship, identity, and motherhood Rituals, mantras, and lessons that keep them grounded Recorded in front of a live audience, this episode blends intention, tradition, and community — followed by a mindful tea tasting led by Radhika. Meet Our Sponsor: WEBSITE: ⁠Get1stWater.com⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

How do you take cutting-edge science and turn it into a tool that actually works for patients? In this episode, Dr. Grant Stevens welcomes Sanjay Batra, CEO of WETHRIVV, to explore the device making topical treatments more effective than ever.With decades of experience in medical research and aesthetics, Sanjay reveals the story behind his innovative approach to enhancing absorption without injections. He explains how this technology is helping practitioners deliver better results for skin rejuvenation and hair restoration — all while keeping treatments simple, safe, and efficient.From exosomes to PRP, Sanjay breaks down how his device is reshaping the future of noninvasive beauty. And with a family-run company built on integrity and scientific rigor, WETHRIVV is leading the charge toward smarter, more accessible regenerative care.If you're ready to see what's next in aesthetics, this is one episode you won't want to miss.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

Dr. Radhika Batra is the Founder, President of Every Infant Matters - fighting malnutrition in children and women, and advocating for maternal health, deworming, promotion of breastfeeding, immunization, and gender equality. Their work has saved 550,000+ malnourished children across India, Nigeria and the Philippines from irreversible blindness. She is a Pediatrician, Neonatologist & Public Health Expert.

Naina Batra, CEO of AVPN, offers a forward-looking and strategic view into the evolution of social investment across Asia. With the upcoming launch of ImpactCollab, AVPN is not merely introducing a platform — it is catalyzing an infrastructure for cross-border philanthropy and capital deployment across Asia's fragmented social impact landscape. AVPN is a social investment network based in Asia and a leading ecosystem-builder that aims to move capital towards impact. ImpactCollab is a platform that has been designed with the support of the Monetary Authority of Singapore and the Bill & Melinda Gates Foundation. It has been designed to address long-standing inefficiencies and trust deficits that hamper giving in the region. It targets a critical and under-leveraged segment: the region's burgeoning population of centi-millionaires and high-net-worth individuals who are eager to give back but often lack the guidance, transparency, and assurance necessary to do so confidently. By functioning simultaneously as a knowledge base, a due diligence engine, and a matchmaking platform, ImpactCollab seeks to bridge the trust gap and remove systemic friction from philanthropic flows. Batra notes this is Asia's moment to lead. Faced with mounting social inequities, climate disasters, and reversals in gender parity and nutrition, the region demands urgent, coordinated responses. AVPN's expansion underscores its commitment to mobilizing a pan-Asian community of social investors — from grantmakers and family offices to development finance institutions and policymakers. An interesting feature of ImpactCollab lies in its governance maturity framework and data-driven nonprofit scorecard. These tools serve dual purposes: instilling confidence in funders while streamlining reporting burdens for nonprofits, many of whom face opaque and restrictive foreign funding environments. AVPN's approach — aggregating capital, reducing duplicative reporting, and embedding transparency — is aimed at producing systemic change. Batra's conviction is clear: wealth in Asia is abundant; what is lacking is a trusted, efficient conduit to mobilize that wealth toward lasting impact. ImpactCollab is AVPN's bold answer to that challenge. Thank you for downloading this episode of the Do One Better Podcast. Visit our Knowledge Hub at Lidji.org for information on 300 case studies and interviews with remarkable leaders in philanthropy, sustainability and social entrepreneurship.  

In this episode of TechSurge, host Sriram Viswanathan sits down with Nishant Batra, Chief Strategy and Technology Officer at Nokia, for a deep dive into the evolving landscape of telecom and wireless technology. Nishant shares insights into the seismic shifts transforming network infrastructure—from core networks to edge computing—and discusses how Nokia leverages artificial intelligence to optimize performance and drive innovation. The conversation also highlights Nokia's unique innovation framework, spanning its corporate venture investments, internal incubator, and expansion of the legendary Bell Labs. Today Nokia leverages Bell Labs' groundbreaking research into emerging technology for internal innovation and new venture spinouts in collaboration with venture capital firms, including recently announced inaugural spinout startup, Astranu.Links:Discover the groundbreaking Nokia-Celesta spinout advancing healthcare imaging technology - Astranu Learn about the legendary innovation powerhouse - Nokia Bell Labs

In this episode, Dr. Romilla Batra, SVP and Chief Medical Officer at Premera Blue Cross, discusses how she's rethinking clinical strategy to align with the quintuple aim, reduce healthcare costs, and enhance equity. She also shares insights on empowering providers, removing barriers to care, and partnering with communities for better health outcomes.

Twenty-two billion! What are we playing at?!Things get worse when we look at the materials most commonly in use. The sports shoe category in particular is a giant, influential sector, yet its waste footprint and chemical inputs tend to fall under the radar. And don't get us started on the Crocsification of everything! Injection-moulded EVA is coming to a clog near you, but don't let's pretend that's sustainable.Increasingly, our shoes are made of frankenstein plastics, and even their creators don't necessarily know what's in them. This week on the podcast, Clare's guest is Chandni Batra, founder of A BLUNT STORY - a disruptive Indian sandals brand on a mission detoxify your footwear, and challenge the industry to stop trashing the planet.This is a gob-smacking conversation full of revelations about how huge numbers of shoes are made today, using oil-based plastics, potentially-toxic foams and petrochemical ingredients for all sorts of uses you've most likely never even heard of. Could these chemicals be leaching into our skin? What are their effects on the environment? And on the workers who must handle them? Why are modern shoes to hard to recycle? And what can be done about all this. Chandni has solutions! Ears here!More info at thewardrobecrisis.comTell us what you think? Find Clare on Instagram @mrspressGot recommendations? Hit us up!And please share these podcasts.THANK YOU. Hosted on Acast. See acast.com/privacy for more information.

Today I am chatting with Chetandeep,About the privacy career he keeps.In addition to privacy, Chetandeep writes books,Author, lawyer, to consultant is the journey he took!

Today's Talmud page, Bava Batra 176, brings us to the end of one of the Talmud's longest and most demanding tractates. Rabbi Dovid Bashevkin joins us to sum it all up. Why does this legalistic tractate contain a collection of wild stories about the Jewish Sinbad, and what do they teach us about coexistence? Listen and find out.

For the text of the Hadran ceremony, click here. For more information about What is a Siyum, click here Siyum Masechet Bava Batra is sponsored by Lesley Glassberg Nadel in loving memory of her father Bernie Glassberg, Berel ben Herschel haLevi, whose 50th yahrzeit is Kislev 17 - May his memory be blessed.

Today's Talmud page, Bava Batra 175, warns us that people will always try to make themselves appear poorer than they are so as to receive a bit more money. But as one of the Torah's greatest heroes, Jacob, teaches us, it's far healthier to do just the opposite. Why is Jacob's mantra "I have become small," and why should we, too, adopt it? Listen and find out.

Study Guide Bava Batra 155 If one says on one's deathbed that money is owed to someone - is that statement believed or should we assume that the person was only trying to make it look like their children do not have a lot of money? Would the same apply in a case where all the money was dedicated to the Temple rather than to the person's children? Can an heir claim that even though their bequeather may have said they owed someone money, they subsequently said they had paid them back? In what case are they believed and in what case are they not believed? What are the differences between a loan with a contract and a loan with an oral agreement? One who has a loan with a document can collect from liened property that has been sold, but an oral loan can only be collected from free (unsold) property. If a guarantor signs after the loan takes place, can one collect from the guarantor, and if so, are there any limitations? Is the property of a borrower liened to the creditor by Torah law or by rabbinic law? Raba and Ulla each take sides on this debate. Rav and Shmuel disagree with Rabbi Yochanan and Reish Lakish whether an oral loan can be collected from orphans or from purchasers. Rav Papa comes up with a unique ruling - not fully matching either position, as he saw a need in society to prevent creditors from refusing to loan money and to prevent a breakdown in the market where buyers are hesitant to purchase land.  

Today's Talmud pages, Bava Batra 173 and 174, give us a stunning example of a very famous rabbi advocating what at first sounds like a complete violation of his own teaching, advising a friend to defraud his own father. But the advice is much more soulful than that, delivering a masterclass on the relationship between love and law. What is the ultimate purpose of rules and regulations, and what does it have to do with our families? Listen and find out.

Today's Talmud pages, Bava Batra 171 and 172, ask how to go about doing business with two people who have the same name. How to keep the records straight? And what did the rabbis understand about the human brain that took neuroscientists millennia to unlock? Listen and find out.

Today's Talmud page, Bava Batra 170, offers a small but inspiring meditation on the true meaning of the justice system, warning us not to forget that every machination we set up must first and foremost serve human beings, flawed as they may be. What should our algorithm-addled and bureaucratic modern society learn from the ancient rabbis about making people feel seen and heard before the law? Listen and find out.

Today's Talmud page, Bava Batra 169, looks at the connection between a written contract and the actual thing you're buying. Should you have to return your Toyota, say, if you happen to simply misplace the lease? And, if not, do words on contracts have any meaning at all? Listen and find out.

Today's Talmud page, Bava Batra 168, issues an incredible instruction: In some earthly matters, Torah scholars should turn and seek help from their bitterest foes, the ignoramuses. Why are experts so frequently wrong? And what can the Talmud teach us about forging a society that focuses not on equity but on excellence? Listen and find out.

Today's Talmud pages, Bava Batra 166 and 167, discuss a dastardly bit of forgery and its subsequent investigation. The Presidentischer Rav Tevi Troy returns to the show to discuss how different presidential administrations have investigated leaks, and how some of these leakers composed their messages in language that would throw suspicion onto their rivals. How has forgery and leaking changed since the days of the Talmud? Listen and find out.

Today's Talmud pages, Bava Batra 164 and 165, caution us not to erase a document after it's been signed and try to write a new one in its stead. What does this seemingly mundane bit of legalese have to do with baseball? And why is it the most Jewish sport imaginable? Listen and find out.

Today's Talmud page, Bava Batra 163, continues the tractate's discussion of documents, signatures, and forgeries. But it also delivers a surprising and potent meditation on true freedom, and on how to live authentically. What's the great lesson Abraham taught us about keeping it real? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 162, deals mainly with how to make sure your documents aren't forged. But as the history of philosophy teaches us, sometimes a little fakery is necessary for brilliant ideas to break through. Who was the great thinker Johannes de Silentio, and how come you've never heard of him yet know his work? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 161, gives us what may very well be the first ever documented appearance of... emoji. Why did some rabbis sign their names using pictograms? And how can emoji sometimes succeed where all words fail? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 159 and 160, contain a ruling that the Talmud considers one of the most difficult cases of civil law. What can it teach us about family? And was Don Corleone really living out some core Talmudic values? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 155, 156, 157, and 158, usher us into Thanksgiving. Rabbi Dovid Bashevkin joins us to explain the strange but undeniable connection between America's favorite holiday and one of the Talmud's most demanding tractates. Why is Bava Batra perfect Thanksgiving reading? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 154, delivers a key lesson in political philosophy disguised as a meditation on inheritance. What's the real difference between conservatives and progressives? And why do both do best when they walk hand in hand? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 152 and 153, the rabbis continue to contemplate our wishes as we lay dying. Rabbi Dovid Bashevkin joins us to talk about the Kittel, the special white and shroud-like garment when we wear not only as we're buried, but also for special festivals like Passover and Yom Kippur. Why wear the same outfit on the saddest and happiest of occasions? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 150 and 151, are a touching tribute to the sanctification of life. Rabbi Dovid Bashevkin joins us to explain the concept of a Shechiv Mera, a person on his deathbed, and why we should pay special attention to his final wishes. What can these deathbed decisions teach us about the meaning of life? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 149, begins with a heartbreaking scene of a father on his deathbed navigating halachic inheritance laws so that he could leave behind his fortune to his son. But study the biographies of these two, and a dark, troubled, and ultimately inspiring story emerges, a story of a man who had done very bad things yet went on to repent. What can Issur the Convert teach us about never, ever losing hope? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 148, asks a thorny question: What happens if someone, on their deathbed, promises to give away all their property but then miraculously recover? Much more than a hypothetical, the question gets to the very bottom of fairness, teaching us much about the promises we must keep and the ones we can safely break. What lesson do the rabbis have for Elton John? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 147, finds the rabbis talking about... the wind, and how it sometimes blows this way and sometimes that, and sometimes makes some people sad and others happy and at other times vice versa. Producer Josh Kross joins us to explain why the passage is actually a perfect political metaphor for our fractured time. What can the Talmud's discussion of the wind teach us about building stronger communities? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 145 and 146, give us a quizzical passage trying to decipher the secret to happiness. How can we make sure we're always feeling joyful? And how did one famous rabbi learn the answer to that question the hard way? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud pages, Bava Batra 143 and 144, negotiate the central tension in Judaism between divine determinism and free will. Rabbi Dovid Bashevkin joins us to explain what catching a cold has to do with our sense of agency in this world. What is divine responsibility, and what is ours? Listen and find out.  Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 142, revolves around a curious question: can an unborn child receive gifts? It's not just a hypothetical thought exercise; it is, as the rabbis teach us, a lesson in prioritizing the real over the ideal. Why should we stop pursuing the perfect and learn instead to grapple with reality in all its complications? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud page, Bava Batra 141, shows us the rabbis once again arguing that God is furious with anyone who doesn't leave behind inheritors. Rabbi Dovid Bashevkin joins us to explain this curious passage, and give us insight into the Talmud view of what truly matters in life. How is having children a reflection of one's values? Listen and find out.  Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud Page, Bava Batra 140, raises a dilemma: As the Torah tells us that sons inherit their fathers, and as Jewish tradition instructs us that fathers must support their unmarried daughters, what happens if a man with both sons and daughters dies and has no money to sustain them both? It's a drama that touches on so much that is human, from family dynamics to the sometimes tense relationship between men and women. How to resolve it? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.

Today's Talmud Pages, Bava Batra 138 and 139, dip in to the age-old battle between introverts and extroverts. Is this distinction even real? And what's the one thing Talmud and science alike tell us you need if you're going to go ahead and grow and change? Listen and find out. Like the show? Subscribe to our weekly newsletter. Send us a note at takeone@tabletmag.com. Follow us on Twitter at @takeonedafyomi and join the conversation in the Take One Facebook group. We think that you may also enjoy Liel's new book How the Talmud Can Change Your Life: Surprisingly Modern Advice from a Very Old Book, available directly from the publisher, or wherever you purchase books. Listen to the Testimonies Archive, a partnership between Tablet Studios and the USC Shoah Foundation, for eyewitness audio accounts from Israel in the wake of the Oct 7 Hamas attacks. Check out all of Tablet's podcasts at tabletmag.com/podcasts.